ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended			36 Months Ended	84 Months Ended
	Feb. 14, 2023	Feb. 28, 2014	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2026	Dec. 31, 2023	Jan. 31, 2023	Mar. 31, 2022	Nov. 30, 2020
Business Acquisition [Line Items]
Acquired IPRD			$ 815	$ 1,159	$ 12,533
Marketing, selling and administrative			7,814	7,690	7,661
Research and development			9,509	10,195	10,048
Royalty Income			832	666	644
Proceeds from divestiture of businesses, net of cash divested			1,157	748	715
Divestiture gain			211	9	55
Turning Point
Business Acquisition [Line Items]
Payments to acquire businesses, gross			4,113
Acquisition, net of cash acquired			3,300
Keytruda Royalties | Forecast
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner							6.50%
Keytruda Royalties | Subsequent Event | Forecast
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner						2.50%
Tecentriq Royalties
Business Acquisition [Line Items]
Proceeds from out-licensed arrangements				324
Patent settlement income				239
Dragonfly
Business Acquisition [Line Items]
Upfront payments for licensing and alliance arrangements					475
Payment for additional targets made to collaborative partner					75
Collaborative arrangement contingent payments maximum exposure					2,700
Dragonfly | Subsequent Event
Business Acquisition [Line Items]
Termination of license								90 days
Nimbus Therapuetics TYK2 Inhibitor
Business Acquisition [Line Items]
Income from settlement			40
Nimbus Therapuetics TYK2 Inhibitor | Subsequent Event
Business Acquisition [Line Items]
Collaborative arrangement contingent payments maximum exposure	$ 2,000
Mavacamten
Business Acquisition [Line Items]
Payment to extinguish future royalty obligation			(295)
Diabetes business
Business Acquisition [Line Items]
Royalty Income			810	622	567
Proceeds from divestiture of businesses, net of cash divested			767	612	558
Divestiture gain			0	0	0
Diabetes business | Minimum
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner		10.00%
Diabetes business | Maximum
Business Acquisition [Line Items]
Percentage of net sales payable to alliance partner		25.00%
Diabetes business | Supply Agreements
Business Acquisition [Line Items]
Royalty Income			924	725	673
Diabetes business | Amelyn, Onglyza, and Farxiga
Business Acquisition [Line Items]
Business sale royalty expense			114	103	106
Mature Brands and Other
Business Acquisition [Line Items]
Divestiture gain			211
Mature Brands and Other | Discontinued Operations, Held-for-sale
Business Acquisition [Line Items]
Assets held for sale			172
Liabilities held for sale			20
Mature Brands and Other | Cost of products sold
Business Acquisition [Line Items]
Asset impairment charges			63
Mature brand, Teofarma
Business Acquisition [Line Items]
Proceeds from divestiture of businesses, net of cash divested				50
Divestiture gain				49
LOTTE Corporation | Mature Brands and Other
Business Acquisition [Line Items]
Sales price			159
Immatics
Business Acquisition [Line Items]
Contingent and regulatory milestone payments			770
License and other arrangements upfront payments									$ 150
Dragonfly
Business Acquisition [Line Items]
License and other arrangements upfront payments			(175)
Agenus
Business Acquisition [Line Items]
Contingent and regulatory milestone payments				1,400
License and other arrangements upfront payments				$ 200
Cheplapharm | Mature Brands and Other
Business Acquisition [Line Items]
Proceeds from divestiture of businesses, net of cash divested			$ 221
MyoKardia Acquisition
Business Acquisition [Line Items]
Consideration paid										$ 13,100
Acquired IPRD					11,400
Assets assumed					1,400
Liabilities assumed					226
Unvested stock awards expensed to marketing, selling and administrative expense and research and development					482
Marketing, selling and administrative					241
Research and development					241
Forbius
Business Acquisition [Line Items]
Consideration paid					185
Contingent and regulatory milestone payments					815
Upfront payment, acquired IPRD					178
Deferred income taxes acquired through an asset acquisition					$ 7
Bristol-Myers Squibb | Keytruda Royalties | Subsequent Event | Forecast
Business Acquisition [Line Items]
Payment and royalty allocation						75.00%
Ono | Keytruda Royalties | Subsequent Event | Forecast
Business Acquisition [Line Items]
Payment and royalty allocation						25.00%
Nimbus Therapeutics | Subsequent Event
Business Acquisition [Line Items]
License and other arrangements upfront payments	$ 4,000
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor
Business Acquisition [Line Items]
Change in control proceeds			10.00%
Nimbus Therapeutics | Nimbus Therapuetics TYK2 Inhibitor | Subsequent Event
Business Acquisition [Line Items]
Percentage of ownership acquired	100.00%